Online citations, reference lists, and bibliographies.
← Back to Search

Optimized Synthesis Of Glycyrrhetinic Acid-modified Chitosan 5-fluorouracil Nanoparticles And Their Characteristics

Mingrong Cheng, Houxiang Chen, Y. Wang, H. Xu, Bing He, J. Han, Zhiping Zhang
Published 2014 · Materials Science, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The nanoparticle drug delivery system, which uses natural or synthetic polymeric material as a carrier to deliver drugs to targeted tissues, has a broad prospect for clinical application for its targeting, slow-release, and biodegradable properties. Here, we used chitosan (CTS) and hepatoma cell-specific binding molecule glycyrrhetinic acid to synthesize glycyrrhetinic acid-modified chitosan (GA-CTS). The synthetic product was confirmed by infrared (IR) spectra and hydrogen-1 nuclear magnetic resonance. The GA-CTS/5-fluorouracil (5-FU) nanoparticles were synthesized by combining GA-CTS and 5-FU and conjugating 5-FU onto the GA-CTS nanomaterial. The central composite design was performed to optimize the preparation process as CTS:tripolyphosphate sodium (TPP) weight ratio =5:1, 5-FU:CTS weight ratio =1:1, TPP concentration =0.05% (w/v), and cross-link time =50 minutes. GA-CTS/5-FU nanoparticles had a mean particle size of 193.7 nm, a polydispersity index of 0.003, a zeta potential of +27.4 mV, and a drug loading of 1.56%. The GA-CTS/5-FU nanoparticle had a protective effect on the drug against plasma degrading enzyme, and provided a sustained release system comprising three distinct phases of quick, steady, and slow release. Our study showed that the peak time, half-life time, mean residence time and area under the curve of GA-CTS/5-FU were longer or more than those of the 5-FU group, but the maximum concentration (Cmax) was lower. We demonstrated that the nanoparticles accumulated in the liver and have significantly inhibited tumor growth in an orthotropic liver cancer mouse model.
This paper references
10.1016/j.addr.2009.10.003
Targeted delivery of low molecular drugs using chitosan and its derivatives.
J. H. Park (2010)
5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells.
K. Johnson (1997)
10.1016/j.colsurfb.2013.03.039
Ellagic acid encapsulated chitosan nanoparticles for drug delivery system in human oral cancer cell line (KB).
V. Arulmozhi (2013)
10.1016/j.actbio.2010.04.021
Glycyrrhetinic acid-modified poly(ethylene glycol)-b-poly(gamma-benzyl l-glutamate) micelles for liver targeting therapy.
W. Huang (2010)
10.3892/IJMM.17.2.215
Glycyrrhetic acid (a metabolic substance and aglycon of glycyrrhizin) induces apoptosis in human hepatoma, promyelotic leukemia and stomach cancer cells.
H. Hibasami (2006)
Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma.
Fumiki Toriumi (2004)
10.4103/2230-973X.82395
Developing micro-/nanoparticulate drug delivery systems using “design of experiments”
Bhupinder Singh (2011)
Polymeric nanoparticles of cholesterolmodified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization
JM Yu (2009)
10.1016/j.ijbiomac.2011.12.034
Design and characterization of antitumor drug paclitaxel-loaded chitosan nanoparticles by W/O emulsions.
J. Xu (2012)
10.3390/md11051644
Response Surface Methodology for Ultrasound-Assisted Extraction of Astaxanthin from Haematococcus pluvialis
Tang-Bin Zou (2013)
10.3390/md8041305
Chitosan Based Polyelectrolyte Complexes as Potential Carrier Materials in Drug Delivery Systems
J. Hamman (2010)
10.1016/0163-7258(90)90091-F
Hepatic circulation: Potential for therapeutic intervention
F. Ballet (1990)
10.1016/j.biomaterials.2013.05.017
Cancer cell-specific photoactivity of pheophorbide a-glycol chitosan nanoparticles for photodynamic therapy in tumor-bearing mice.
In-hyeok Oh (2013)
10.1211/0022357023691
Nanosuspensions: a promising drug delivery strategy
V. Patravale (2004)
10.2147/IJN.S43555
Application of the central composite design to optimize the preparation of novel micelles of harmine
Yong-yan Bei (2013)
10.1016/j.colsurfb.2008.07.020
Chitosan-coated magnetic nanoparticles as carriers of 5-fluorouracil: preparation, characterization and cytotoxicity studies.
L. Zhu (2009)
10.1073/PNAS.95.8.4607
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment.
S. Hobbs (1998)
10.1016/j.ejpb.2010.12.031
Layer-by-layer assembly of poly(L-glutamic acid)/chitosan microcapsules for high loading and sustained release of 5-fluorouracil.
Shifeng Yan (2011)
10.1016/0005-2736(91)90253-5
Specific binding of glycyrrhetinic acid to the rat liver membrane.
M. Negishi (1991)
10.1016/S1043-6618(02)00121-4
Hepatoprotective effects of 18beta-glycyrrhetinic acid on carbon tetrachloride-induced liver injury: inhibition of cytochrome P450 2E1 expression.
H. Jeong (2002)
10.1016/j.nano.2011.11.002
Self-assembly and liver targeting of sulfated chitosan nanoparticles functionalized with glycyrrhetinic acid.
Q. Tian (2012)
10.2174/138920008785821693
Decreasing systemic toxicity via transdermal delivery of anticancer drugs.
Jia-You Fang (2008)
10.2174/138955711796575443
Structure-activity relationship analyses of glycyrrhetinic acid derivatives as anticancer agents.
B. Lallemand (2011)
10.3109/03639045.2010.487263
Application of rotatable central composite design in the preparation and optimization of poly(lactic-co-glycolic acid) nanoparticles for controlled delivery of paclitaxel
S. Kollipara (2010)
10.1111/cbdd.12145
Chitosan‐Coated Superparamagnetic Iron Oxide Nanoparticles for Doxorubicin Delivery: Synthesis and Anticancer Effect Against Human Ovarian Cancer Cells
A. Javid (2013)
10.1016/j.ijpharm.2010.06.029
Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery.
Z. He (2010)
10.1211/jpp.61.06.0003
Polymeric nanoparticles of cholesterol‐modified glycol chitosan for doxorubicin delivery: preparation and in‐vitro and in‐vivo characterization
Jingmou Yu (2009)
10.1023/A:1015803321609
Optimized Formulation of Magnetic Chitosan Microspheres Containing the Anticancer Agent, Oxantrazole
E. E. Hassan (2004)
10.1016/j.biomaterials.2010.02.042
Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery.
Q. Tian (2010)
10.1016/S1359-6446(03)02988-X
Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress.
F. Marcucci (2004)
10.1089/jop.2012.0184
Sustained release of 5-fluorouracil from chitosan nanoparticles surface modified intra ocular lens to prevent posterior capsule opacification: an in vitro and in vivo study.
X. Huang (2013)
10.1007/s10856-011-4262-2
Glycyrrhetinic acid-functionalized degradable micelles as liver-targeted drug carrier
W. Huang (2011)



This paper is referenced by
10.1080/10717544.2019.1636422
Preparation and in vitro and in vivo evaluations of 10-hydroxycamptothecin liposomes modified with stearyl glycyrrhetinate
T. Zhou (2019)
10.2147/IJN.S135626
Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier
Yongjiu Lv (2017)
10.1016/j.jconrel.2015.08.056
Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy.
M. Dobrovolskaia (2015)
10.1016/j.taap.2015.12.022
Current understanding of interactions between nanoparticles and the immune system.
M. Dobrovolskaia (2016)
10.1070/RCR4707
Development of liver cell-targeted drug delivery systems: experimental approaches
Y. Ivanenkov (2017)
10.1007/s11356-020-07608-8
Development, larvicide activity, and toxicity in nontarget species of the Croton linearis Jacq essential oil nanoemulsion
J. Amado (2020)
10.1016/j.critrevonc.2020.102968
Nanotheranostics: Their role in hepatocellular carcinoma.
Rama Rao Malla (2020)
10.1517/17425247.2015.1042857
Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics
M. Dobrovolskaia (2015)
10.1016/J.JDDST.2015.11.009
Fabrication of acetylated dioscorea starch nanoparticles: Optimization of formulation and process variables
G. Paulos (2016)
10.1208/s12248-015-9761-5
Poly(butylcyanoacrylate) and Poly(ε-caprolactone) Nanoparticles Loaded with 5-Fluorouracil Increase the Cytotoxic Effect of the Drug in Experimental Colon Cancer
R. Ortiz (2015)
10.1002/mabi.202000312
Biomedical and Pharmacological Uses of Fluorescein Isothiocyanate Chitosan-Based Nanocarriers.
Anna E Caprifico (2020)
10.5497/WJP.V4.I1.96
Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement
M. L. Cuestas (2015)
10.1016/j.toxrep.2019.08.007
Effect of co-administration of Bee honey and some chemotherapeutic drugs on dissemination of hepatocellular carcinoma in rats
Naima Zayed Mohamed (2019)
10.1016/b978-0-323-42863-7.00011-6
Nanobiomaterial-based delivery of drugs in various cancer therapies
A. Pandurangan (2016)
10.1016/j.bbagen.2014.06.004
Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment.
A. Anitha (2014)
10.1039/C6TB01348A
Folate grafted thiolated chitosan enveloped nanoliposomes with enhanced oral bioavailability and anticancer activity of docetaxel.
M. Sohail (2016)
10.1107/S2052520614026419
Solid-state supramolecular architecture of carbenoxolone – comparative studies with glycyrrhetinic and glycyrrhizic acids.
E. Tykarska (2015)
10.3390/pharmaceutics12010082
Mechanism and Improved Dissolution of Glycyrrhetinic Acid Solid Dispersion by Alkalizers
Luning Dong (2020)
10.21608/EJM.2018.5057.1072
In vitro Detection of Antibacterial Activity of Glycyrrhizic Acid Nanoparticle against ESBL Producing Klebsiella pneumoniae strains
M. Abdel-Mongy (2018)
Semantic Scholar Logo Some data provided by SemanticScholar